Bausch Health's Securities Litigation Casts Shadow Over B+L's Future As Independent Firm

For all B+L has going for it, including consumer health eye health and vision care products as its sales driver, it could be stymied by investors alleging Bausch Health conducted fraudulent conveyance by spinning out B+L through an IPO in 2022.

• Source: Shutterstock

More from Legal

More from Policy & Regulation